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Abstract: Advances in acute stroke therapy resulting from thrombolytic treatment, 
endovascular procedures, and stroke units have improved significantly stroke survival and 
prognosis; however, for the large majority of patients lacking access to advanced therapies 
stroke mortality and residual morbidity remain high and many patients become 
incapacitated by motor and cognitive deficits, with loss of independence in activities of 
daily living. Therefore, over the past several years, research has been directed to limit the 
brain lesions produced by acute ischemia (neuroprotection) and to increase the recovery, 
plasticity and neuroregenerative processes that complement rehabilitation and enhance  
the possibility of recovery and return to normal functions (neurorepair). Citicoline has 
therapeutic effects at several stages of the ischemic cascade in acute ischemic stroke and 
has demonstrated efficiency in a multiplicity of animal models of acute stroke. Long-term 
treatment with citicoline is safe and effective, improving post-stroke cognitive decline  
and enhancing patients’ functional recovery. Prolonged citicoline administration at  
optimal doses has been demonstrated to be remarkably well tolerated and to enhance 
endogenous mechanisms of neurogenesis and neurorepair contributing to physical therapy 
and rehabilitation. 
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1. Introduction 
Each year, about 22 million people worldwide suffer a stroke. Stroke is a global health-care 
problem that causes a substantial burden of disease and remains one of the most devastating public 
health problems, often resulting in death or severe physical impairment and disability. According to 
the Global Burden of Disease Study 2010 [1] in the last decade stroke became the third-most-common 
global cause of disability-adjusted life years (DALYs), second only to ischemic heart disease [1]. 
Increase in vascular risk factors—in particular, high blood pressure, tobacco smoking, alcohol, and 
poor diets—appears to be responsible for this increase [1]. Although effective primary prevention can 
be achieved with measures controlling vascular risk factors, at present, there are only two effective 
evidence-based treatments for stroke: stroke unit care and thrombolysis with alteplase (recombinant 
tissue plasminogen activator, rtPA). 
Ischemic stroke is a dynamic process whereby the longer the arterial occlusion persists the larger 
the infarct size becomes and the higher the risk of post-perfusion hemorrhage. The goal of ischemic 
stroke treatment is to reopen the occluded artery. The only treatment that has demonstrably been able 
to halt the dynamic process launched by the vessel occlusion is rtPA that increases five times the odds 
of early recanalization (in the first 6 h), resulting in a decrease in infarct size with better neurologic 
and functional outcome of the patient [2]. Currently, intravenous fibrinolysis can be administered 
safely within the first 4.5 h following stroke onset [3]; and even as late as 6 h when an arterial 
occlusion is demonstrated with presence of potentially salvageable tissue (ischemic penumbra). In 
these late cases, the results of fibrinolysis treatment are similar to those of earlier windows in terms of 
arterial recanalization, functional recovery and frequency of hemorrhagic transformation [4]. 
Intravenous thrombolysis can be reinforced with ultrasound-enhanced treatment or 
sonothrombolysis [5] and ultrasound plus microbubbles [6]. Arterial recanalization in acute stroke can 
also been achieved by interventional neurovascular treatments including combined i.v. thrombolysis 
plus intra-arterial rescue in cases refractory to i.v. rtPA thrombolysis [7]. In acute stroke patients where 
rtPA is contraindicated other therapeutic options include primary intra-arterial thrombolysis and/or 
mechanical thrombectomy [8]. 
A recent systematic review and meta-analysis comparing intra-arterial thrombolysis vs. standard 
treatment or intravenous thrombolysis in adults with acute ischemic stroke demonstrated a modest 
benefit of intra-arterial thrombolysis over standard treatment, although no clear benefit was found  
for intra-arterial thrombolysis over intravenous thrombolysis in acute ischemic stroke patients [9]. 
However, there was an almost fourfold increase in risk of intracranial hemorrhage (RR = 3.90; 95% CI 
1.41–10.76; p = 0.006) with intra-arterial thrombolysis [9]. In a study conducted by Álvarez-Sabin and 
colleagues [10], diffusion-weighted magnetic resonance imaging (DW-MRI) was performed in a group 
of patients with acute ischemic stroke involving the middle cerebral artery (MCA) territory. Initial 
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DW-MRI was obtained within 6 h after ictus and was repeated 36–48 h later; images demonstrated 
increased size of the lesions in 77% of the patients. However, lesion-size increase was significantly 
smaller in those treated with i.v. rtPA than in those untreated (57.7% vs. 234.7%). 
Therefore, recanalization treatment only controls partially the biochemical and molecular events 
triggered by cerebral ischemia, indicating that other factors must be controlled [11,12]; such factors 
include, but are not limited to, collateral blood flow, body temperature, hyperglycemia [13–16], and 
blood pressure fluctuations. Ideally, sufficient protection must be provided to the ischemic brain 
(neuroprotection) along with enhanced recovery of the damaged brain (neurorepair). 
Finally, incorporating stroke unit care and thrombolysis into medical services is difficult and even 
impossible in many low- and middle-income countries—which have the greatest burden of stroke—
because the required high levels of infrastructure, expertise, and resources are unavailable. Therefore, 
safe and effective neuroprotective drugs that could be given at medical services with limited resources 
would improve the outcome of millions of acute stroke patients. 
2. Ischemic Neuroprotection: Brain Protection 
Ischemic neuroprotection (brain protection) may be defined as any strategy, or combination of 
strategies, that antagonizes, interrupts, or slows down the sequence of injurious biochemical and 
molecular events that, if left unchecked, eventually result in irreversible ischemic injury [12]. 
Neuroprotection attempts to limit the brain damage produced by ischemia. 
Experimental studies have demonstrated the complexity of the pathophysiology of stroke [17–20]. 
Among others, it involves excitotoxicity mechanisms [18], oxidative stress damage [19–21], 
inflammatory pathways [22,23], ionic imbalances, apoptosis, and angiogenesis [24,25] that are 
potential targets being evaluated in clinical trials [17,18]. Although successful in experimental  
models, translation to bedside treatments has been disappointing and complicated by some of the 
following reasons: 
1. There is a need to protect the entire neurovascular unit that comprises neurons, glia, pericytes 
and blood vessels [26,27]. For many years the goal was to salvage neurons in the ischemic 
penumbra but recently it became clear that this goal is insufficient and that all the elements of 
the neurovascular unit must be rescued from ischemia [28]. 
2. Many of the potential targets have a biphasic cycle whereby the same mediator or molecule 
plays a different role under pathologic or physiological conditions. For instance, in the earliest 
phase of ischemic stroke the excitatory glutamate NMDA receptors become hyperactive and 
mediate cell death, but these same receptors are critical for neurogenesis and neuronal plasticity 
during the recovery phase of stroke. A similar mechanism occurs with metalloproteases [29–34] 
that contribute to the breakdown of the blood brain barrier (BBB) enlarging the ischemic lesion 
but are critical also for angiogenesis during the recovery phase. 
Therefore, better animal models are required to explore the complexity of acute ischemic stroke. 
The use of preclinical STAIR criteria [35] provides adequate guidelines but even the strict adherence 
to these criteria does not predict clinical success. 
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delivering citicoline in direct contact with ischemic neurons in a MCA occlusion model in rats,  
Xu et al. [43] demonstrated optimal effects of citicoline administration by this stereotactic delivery 
method under MRI guidance. 
Citicoline has therapeutic effects at several stages of the ischemic cascade in acute ischemic  
stroke. First, it stabilizes cell membranes by increasing phosphatidylcholine and sphingomyelin 
synthesis [37,44] and by inhibiting the release of free fatty acids [45]. By protecting membranes, 
citicoline inhibits glutamate release during ischemia. In an experimental model of ischemia in the rat, 
citicoline treatment decreased glutamate levels and stroke size [46]. Caspase is activated in human 
stroke [47] and citicoline has been shown to decrease the release of damaging caspase activation 
products [48] inhibiting apoptosis in animal models of brain ischemia [23]. Citicoline favors the 
synthesis of nucleic acids, proteins, acetylcholine and other neurotransmitters, and decreases free 
radical formation [49,50]. Therefore, citicoline simultaneously inhibits different steps of the ischemic 
cascade protecting the injured tissue against early and delayed mechanisms responsible for ischemic 
brain injury. Finally, citicoline may facilitate recovery by enhancing synaptic outgrowth and increased 
neuroplasticity [50] with decrease of neurologic deficits and improvement of behavioral performance, 
as well as learning and memory tasks [40]. 
4. Clinical Experience with Citicoline in Stroke Patients 
For the past two decades, multiple randomized clinical stroke trials on citicoline reported the 
effectiveness of this pharmacological intervention when used early after onset of ischemia, as 
demonstrated by improvements in level of consciousness and modified Rankin score [51]. Given that 
various populations of stroke patients were included in these studies using different sample sizes, 
multiple doses, and several outcome endpoints, it became difficult to reach valid conclusions. Most 
studies, however, demonstrated a positive effect with the use of citicoline during the acute and 
subacute phases of ischemic stroke [52]. For instance, the ECCO 2000 trial [53] included 90 patients 
that underwent diffusion-MRI prior to the onset of the treatment and a second one with T2 sequences 
12 weeks later. Patients treated with 2 g daily of citicoline orally had an initial lesion volume of 62 mL 
and this was reduced six weeks later to 17 mL; in comparison with controls, the MRI reduction in 
infarct size was statistically significant [53]. Moreover, 70% of the patients with clinical improvement 
of greater than seven points in the NIH stroke scale had smaller stroke size compared with 42% in 
those without clinical improvement. 
5. Data Pooling Analyses 
In 2002, we performed a data pooling analysis to determine the effect of citicoline on neurological 
and functional recovery three months after moderate to severe stroke (baseline NIH ≥ 8) in comparison 
with placebo [54]. The main outcome measure was global improvement using Generalized Estimating 
Equations (GEE analysis), i.e., the degree of neurological and functional recovery represented by  
the global scores of the NIH Stroke Scale (NIH-SS ≤ 1), Barthel’s Index (BI ≥ 95%) and the  
modified Rankin score (mRS ≤ 1). This study reviewed all randomized double-blind, parallel,  
placebo-controlled studies performed in patients with ischemic stroke treated with either citicoline or 
placebo within the first 24 h of the onset of symptoms and during a period of six weeks. The daily oral 
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doses used ranged from 500 mg, 1000 mg, to 2000 mg. The patients included fulfilled the following 
criteria: age ≥ 18 years, randomized within the first 24 h after onset of stroke symptoms, persistent 
deficits for >60 min, brain CT and/or MRI compatible with the diagnosis of stroke, symptoms 
suggestive of acute ischemia in the MCA territory, baseline NIH score ≥ 8 (with at least two points 
from motor deficit), and mRS ≤ 1 prior to the stroke. Finally, subjects had none of the following 
exclusion criteria: brain CT/MRI with other structural lesions, serious systemic disease, unstable 
cardiovascular disease, pre-existing disability and/or psychiatric disease or dementia. 
Following a comprehensive review, a total of 1372 patients were included in the data pooling 
analysis, 789 treated with citicoline and 583 with placebo, from four controlled clinical trials 
performed in the USA [55–58]. After 12 weeks of treatment 25.2% of the patients treated with 
citicoline presented complete recovery compared with only 20.2% of the placebo-treated cases  
(OR 1.33; 95% CI 1.10–1.62; p = 0.0034). As mentioned above, patients included in the data pooling 
analysis received three different daily doses of citicoline: 500 mg, 1000 mg or 2000 mg; the group 
treated with 2000 mg/day had statistically significant better prognosis with a 38% higher probability of 
complete recovery at 12 weeks (Figure 2) compared with those at lower doses. 
Figure 2. Probability of total recovery according to daily dose of citicoline among patients 
included in the pooled data analysis (N = 789 subjects on citicoline compared with 583  
on placebo). 
 
Upon individual analysis of each one of the three variables that conform to the main global variable, 
it was determined that improvement occurred both with neurological deficits measured by the NIH-SS, 
as well as with functional scales (BI and mRS). In comparison with placebo-treated subjects,  
citicoline-treated patients reached a higher percentage of complete neurological and functional 
recovery. This was particularly clear with mRS scores (OR 1.42; 95% CI 1.08–1.88; p = 0.013).  
There were no differences in side effects or number of cases withdrawing from the trial between the 
two groups. 
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In summary, the results of the data pooling analysis concluded that patients with moderate to severe 
ischemic stroke (NIH ≥ 8) treated with citicoline orally within 24 h of onset for a period of six weeks 
demonstrated a statistically significant increase of 33% in the probability of achieving complete 
recovery at 12 weeks; furthermore, it was demonstrated that citicoline is a safe medication. 
A meta-analysis by Sever [59] of 10 controlled clinical trials using citicoline studied 2279 patients, 
including both ischemic and hemorrhagic stroke distributed as follows, ischemic stroke: 1278 (1171 on 
citicoline vs. 892 controls) and 215 intracerebral hemorrhages (107 on citicoline vs. 109 controls). This 
meta-analysis demonstrated similar results to those of the data pooling analysis. In comparison with 
placebo, patients treated with citicoline showed significant reduction in the frequency of death or 
disability at follow-up (57.0% vs. 67.5%; OR 0.64; 95% CI 0.54–0.77; p < 0.001). Safety analysis 
showed no adverse effects in comparison with placebo (14.5% vs. 14.0%; OR 0.99; 95% CI 0.77–1.21; 
p = 0.94). 
6. The ICTUS Trial 
The International Citicoline Trial on Acute Stroke, ICTUS [60] was designed to confirm the 
encouraging results of the data pooling analyses and to replicate those trends. ICTUS was an 
international, multicenter, prospective, double-blind, randomized, placebo-controlled trial with 
participation of neurology services from 37 centers in Spain, 11 in Portugal, and 11 in Germany. 
Patients were randomized in a 1:1 ratio to citicoline or placebo. Citicoline was dosed at 2000 mg/day 
during six weeks; in the first three days it was given intravenously (1000 mg/12 h) and orally from the 
4th day on for six weeks (two tablets 500 mg/12 h). 
The main objective of the study was to confirm the results of the data pooling analysis; i.e., to 
determine the overall effects of citicoline on moderate to severe ischemic stroke recovery (NIHSS at 
baseline ≥8) after three months of therapy with 2000 mg/day of citicoline (six weeks of treatment and  
6 weeks of follow-up) in comparison with placebo. The global variable previously used in the data 
pooling analysis was the main end-point, with three components: neurological deficit (NIH-SS ≤ 1), 
functional capacity (mRS ≤ 1) and activities of daily living (BI ≥ 95). The main global variable was 
studied using GEE analysis. 
The results were as follows [60]: from a total of 2298 patients enrolled into the study 1148 were 
assigned to citicoline and 1150 to placebo. The trial was stopped for futility at the 3rd interim analysis 
on the basis of complete data from 2078 patients. Global recovery at 90 days was similar in both 
groups. The median unbiased estimate of the adjusted odds ratio of the primary efficacy endpoint was 
1.03 (95% CI 0.86–1.25). The odds ratios were also neutral in the sub-groups defined by minimization 
factors. Similar results were reported for each one of the secondary objectives (mRS ≤ 1, NIHSS ≤ 1, 
Barthel index ≥95). Mortality was comparable between the two groups (19% in the citicoline group vs. 
21% in the placebo group). Adverse events occurred with similar frequency in both groups. 
Symptomatic hemorrhagic transformation occurred in 6% of patients who received citicoline and  
8% of patients assigned to placebo (p = 0.25) [25]. 
The following are the main conclusions derived from the results of the ICTUS trial: 
- Citicoline had no significant effect on the risk of hemorrhage from rtPA and had a comparable 
safety and tolerability profile compared to placebo. 
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- Global recovery at 90 days was similar in patients who received citicoline and in those  
who received placebo. Results were also neutral in the secondary endpoints and in the 
predetermined protocol analyses. 
- Under the circumstances of the ICTUS trial, citicoline is safe but does not provide efficacy 
evidence for the treatment of moderate-to-severe acute ischemic stroke. 
Some important characteristics of the ICTUS trial probably influenced the results: 
1. Patients had more severe strokes in the ICTUS trial, as demonstrated by the NIH-SS 15 [11–19] 
vs. 14 [10–18] in previous studies; this renders more difficult the demonstration of a favorable 
effect; the main end-point required global improvement of both neurological and functional 
measurements. In fact, in the ICTUS trial the mRs 0–2 was 29% vs. 39% for pooled cases. 
2. It is conceivable that larger doses for a longer period could have had a positive effect. In the 
previously noted meta-analysis of experimental data [41] greater reduction of infarct volume 
occurred in rats treated with larger doses of citicoline (300–500 mg/kg), along with superior 
recovery (27%; 95% CI 9–46) in comparison with animals treated with lower doses  
(100–300 mg/kg) with 18% recovery (95% CI 5–32; p > 0.001). Larger reduction of stroke 
volume was also documented in another study [61]; moreover, citicoline at high doses is as 
effective as i.v. thrombolysis in experimental stroke [62]. 
3. Patients enrolled in the ICTUS trial were not required to have neuroimaging studies of ischemic 
penumbra. Therefore, it was impossible to determine if at the onset of therapy salvageable brain 
tissue was present; moreover, this lack of images prevented accurate evaluation of stroke 
evolution. The latter is highly relevant given that in the ECCO 2000 Citicoline Trial—DWI  
Sub-study a comparison of DW-MRIs obtained at baseline with T2 MR images at week 12 of 
treatment with citicoline (2 g/day for six weeks) showed a significant decrease in volume of the 
cortical lesion [53]; this reduction in lesions size was associated with better clinical outcome, as 
mentioned above. 
4. Finally, a substantial number of patients received i.v. rtPA rendering the analysis of the results 
more difficult since many patients reached the maximum possible recovery with the 
thrombolytic treatment. Thus, a ceiling effect resulting from an already maximal improvement 
due to rtPA effect cannot be ruled out. Almost half of the patients (47%) in the ICTUS trial 
received i.v. rtPA compared with only 13% in the pooled data analyses. Additionally, the trials 
were done 10 years apart, a period of time during which the standard of stroke care has  
improved substantially. 
7. Hemorrhagic Stroke 
A single clinical trial (FI-CDPc-HIC) has used citicoline in patients with hemorrhagic stroke [63]. 
This was a pilot, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety 
of citicoline in patients with acute intracerebral hemorrhage (AICH). The study enrolled patients aged 
40–85 years old with a primary hemispheric supratentorial hemorrhage within less than 6 h of 
evolution. Patients were treated with placebo or citicoline 1 g/12 h i.v. during the first week and then 
orally. Safety analysis showed no differences with placebo in terms of adverse effects, mortality or 
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study withdrawals. The results showed that 6.7% of the patients treated with placebo had reached 
independence (Rankin 0–2) at 12 weeks compared with 27.8% of those on citicoline. In conclusion, 
citicoline is a safe and effective pharmacological product in patients with AICH and can be used in 
acute stroke patients even before images are obtained to separate ischemic from hemorrhagic stroke. 
8. Brain Neurorepair 
Spontaneous recovery of function occurs naturally after stroke in both humans and in animal 
models. This functional recovery is generally incomplete and results from reversal of diaschisis, 
activation of cellular genesis, repair mechanisms, change in the properties of the existing neuronal 
pathways and stimulation of neuronal plasticity leading to new neuronal connections [64,65]. 
In patients with ischemic stroke neurological recovery occurs over a period of three months, and 
this is the usual evaluation time for final outcome in neuroprotection trials. However, recovery is only 
possible when neurorepair occurs, including not only repair of the damaged neurons, but also 
enhancement of angiogenesis [66] and brain plasticity (neuronal and synaptic). 
The adult human brain has the capacity to undergo physiological and anatomical modifications 
leading to motor and cognitive recovery [67]. Cerebral ischemia launches concurrently neurogenesis 
and angiogenesis, two closely interconnected processes that enhance neural repair. 
There is definitive evidence that neurogenesis occurs in the adult brain following a stroke. 
Endogenous progenitor neural stem cells are normally present in the normal brain and maintain the 
capacity to produce new neurons and glial cells during adult life. Progenitor neural stem cells capable 
of producing neuroblasts in the adult human brain are situated in the subventricular zone of the lateral 
ventricle and in the dentate gyrus of the hippocampus. Under physiological conditions the neuroblasts 
of the subventricular zone migrate towards the olfactory bulb where they are transformed into neurons. 
In response to brain ischemia, the adult progenitor neural cells proliferate in the ipsilateral 
subventricular zone and migrate towards the zone surrounding the infarction where they mature into 
adult neurons that may become part of functional neuronal circuits [68]. 
Neuropathological studies have shown the increase in cellular proliferation and in neuroblasts in the 
subventricular zone in patients who died shortly after an acute ischemic stroke [68]. However, many of 
the newly formed immature neurons and neural cells die and are never integrated into functional 
neuronal circuits. For this reason, it is important to develop novel cellular and pharmacological 
strategies to increase neurogenesis leading to functional neuronal circuits. Repair of focal cortical 
strokes [69] is not done by neuroblasts migrating from the subventricular zone but from clonal  
neural spheres originating from the peri-infarct area that differentiate into neurons, astrocytes, 
oligodendrocytes, and smooth muscle cells. 
Angiogenesis [66] is one of the main components of the processes of post-ictal neurovascular 
remodeling. It induces capillary neoformation in response to proliferation and migration of primordial 
stem cells originating from the existing blood vessels. The pericytes appear to have a major role in 
neurogeneration responses. The pericyte is a pluripotent stem cell in the brain with the potential of 
differentiating into cells of neural lineage such as astrocytes, oligodendrocytes and neurons [70]. 
Angiogenesis can be observed several days following an ischemic stroke and it has been shown that  
a higher capillary density correlates with longer survival. Proangiogeneic factors such as vascular 
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endothelial growth factor or VEGF [71], and metalloproteinases increase following cerebral ischemia. 
The effect of angiogenesis is to increase collateral circulation to meet the metabolic demands in  
terms of oxygen, glucose and nutrients required by the damaged and repaired tissues. Also, the newly 
generated blood vessels provide the neurotrophic support required by neurogenesis and synaptogenesis 
that eventually lead to functional recovery. In summary, angiogenesis provides the stimulation 
required to launch and enhance endogenous mechanisms repair and recovery including neurogenesis 
and synaptogenesis, as well as neuronal and synaptic plasticity. These events are all involved in the 
long-term repair and restoration process that take place in the brain after acute or chronic ischemic 
events [72]; therefore, angiogenesis is one of the most promising areas of research in the field of stroke 
treatment [66,67]. 
9. Neurorepair Therapies 
Repair therapies aim to restore the brain, a goal that differs from that of neuroprotection therapies, 
in which the aim is to limit acute stroke injury. A number of potentially useful post-stroke 
interventions are currently being evaluated, such as the “mirror therapy” [73] that is simple and useful 
to apply in addition to traditional physical therapy and rehabilitation treatments. Neuromuscular 
electrical stimulation has been found to improve neuromuscular function and to stimulate cerebral 
plasticity [74]. 
Transcranial magnetic stimulation [75], in addition to physical and occupational therapy, 
significantly improves motor function. Improvement is due to stronger stimulation of intact motor 
cortical regions homolateral to the hemiplegic side [75]. 
The NEST-3 (NeuroThera® Efficacy and Safety Trial-3) trial [75] is currently being conducted. 
This is a multicenter, double-blind, randomized, placebo-controlled pilot study with parallel groups  
to evaluate the safety and efficacy of a transcraneal laser stimulation with the NeuroThera® Laser 
System in patients within 24 h of an acute ischemic ictus. Finally, there is an enormous potential with 
the use of robotic therapy after stroke [75]. 
A number of medications have been used to enhance recovery and tissue repair following ischemic 
stroke. Among the anti-depressants, serotonine uptake inhibitors (SSRIs) and noradrenergic inhibitors 
have been demonstrated to improve motor recovery in patients with ischemic stroke [76,77]. The 
mechanism of action of SSRIs is unknown. Acler and colleagues [78] described decreased excitability 
of the threshold of the contralateral motor cortex after one month of use of citalopram. Decreased 
contralateral threshold increases motor recovery; neurogenesis and synaptic plasticity when the 
treatment is used for periods as long as one year. Valproic acid treatment appears to decrease stroke 
size in experimental stroke in rats, probably by enhancing angiogenesis in the hemisphere ipsilateral to 
the arterial occlusion [79]. 
10. Citicoline and Brain Neurorepair 
In addition to the neuroprotective effects, citicoline also possesses a substantial neuroregenerative 
potential that may explain better its long-term beneficial effects in post-stroke patients. 
In an experimental stroke model with permanent occlusion of the distal MCA in mice citicoline 
(500 mg/kg) or vehicle was administered 24 h later intraperitoneally for 1–2 weeks. Citicoline 
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treatment decreased neuronal apoptosis and promoted endogenous cerebral repair [80]. A well-known 
experimental study conducted at Madrid’s Complutense University demonstrated that treatment with 
citicoline 24 h after MCA occlusion in rats produced an increase in neuronal synaptic spines with 
increased motor and functional recovery in treated animals [50]. 
Endothelial progenitor cells (EPCs) are circulating immature pluripotential hematopoietic cells 
capable of differentiating into mature endothelial cells to help in the recovery of capillary and vascular 
recovery of ischemic areas. EPCs also promote growth factor release and increase neurogenesis. The 
increase in circulating EPCs after acute ischemic stroke is associated with good functional outcome, 
reduced infarct growth and neurological improvement. It has been shown that increase in EPCs in 
peripheral blood in acute stroke patients improves functional recovery and decrease stroke size [81].  
In a prospective study including 48 patients with a first-ever non-lacunar stroke citicoline treatment 
and the co-treatment with citicoline and rt-PA are independently associated with a higher increase in 
circulating EPCs during the first week in acute ischemic stroke [82]. Gutiérrez-Fernández et al. [83] 
demonstrated in an experimental model of stroke in rats that treatment with CDP-choline significantly 
improved functional recovery associated with a decrease in lesion volume by MRI, less cell death and 
decreased expression of low-density lipoprotein receptor-related protein (LRP). In fact, CDP-choline 
increased cell proliferation, vasculogenesis and synaptophysin levels and reduced glial fibrillary acidic 
protein (GFAP) levels in the peri-infarct area of the ischemic stroke. A more recent study on 40 rats 
treated at 24 h of experimental stroke with citicoline during 10 days showed significant improvement 
in both motor and somatosensory recovery by increasing neurogenesis in the peri-infarct area, 
subventricular zone and dentate gyrus [84]. 
In summary, citicoline enhances both brain neuroprotective and neurorepair mechanisms following 
ischemic stroke. These mechanisms are illustrated in Figure 3. 
11. Citicoline in Post-Stroke Cognitive Decline 
Cognitive and behavioral manifestations are frequently observed in patients with vascular cognitive 
impairment and vascular dementia. Cognitive impairments occur in nearly half of stroke  
survivors [85], a frequency more elevated than that of stroke recurrence. These impairments may be 
more important determinants of functional outcomes after stroke than physical disability [86,87]. 
Most end-points used in clinical trials address issues relevant to motor function, activities of daily 
living and quality of life; in fact, many patients with cognitive or behavioral problems are excluded 
from clinical trials. Therefore, there is a need to identify cognitive and behavioral problems occurring 
as a result of stroke or “silent” small-vessel vascular disease. For the above reasons, International 
Guidelines recommend routine cognitive and behavioral evaluation of stroke patients [88]. In reality, 
these aspects are rarely evaluated in stroke patients [89]. Along the same lines, few pharmacological 
products have been evaluated for prevention or treatment of cognitive problems in the stroke patient. A 
Cochrane meta-analysis of citicoline in 942 patients with vascular cognitive impairment studied in  
12 placebo-controlled, double-blind, randomized studies showed modest evidence of improvement in 
memory and behavior, and a significant impression of improvement on the global impression  
of change on the part of caregivers [90]. Based on these data and on abundant evidence on the 
neuroprotective and neurorepair effects of citicoline, we evaluated the safety and efficacy of citicoline 
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on the cognitive manifestations of patients with acute ischemic stroke. This study was an open-label, 
randomized, parallel study of citicoline (1 g/day) for 12 months vs. usual treatment in patients  
with first-ever ischemic stroke [91]. Citicoline-treated patients showed better outcome at follow-up in 
attention-executive functions and temporal orientation at six months and 12 months (Figure 4). 
Moreover, although differences are not statistically different, patients treated with citicoline showed a 
trend towards having a better functional outcome, measured with mRS at 6 and 12 months (Figure 5). 
Figure 3. Major mechanisms involved in brain plasticity. The diagram explains the  
actions of citicoline to enhance the processes of inhibition of apoptosis [48],  
angiogenesis [92], neurogenesis [84], gliagenesis [93], synaptogenesis [50], and 
modulation of neurotransmitters [84]. Notice that all these effects are similar to those 
induced by stem cells. 
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Figure 4. Functional status during follow-up: Notice the improvement in mRS scores (<2) 
at six and 12 months following stroke in the group treated with citicoline, compared with 
those untreated. From Álvarez-Sabín et al. [91]. 
 
Figure 5. Functional status during six month follow-up: Subjects treated with citicoline  
had improvement on all cognitive domains; however, improvement was statistically 
significant only for attention/executive function and temporal orientation. Modified from 
Álvarez-Sabín et al. [91].  
 
12. Expert Opinion 
In conclusion, citicoline, a naturally occurring endogenous compound, is a key intermediary in the 
biosynthesis of phosphatidylcholine. Long-term treatment with citicoline is remarkably safe and has 
demonstrated therapeutic effects at several stages of the ischemic cascade in acute ischemic stroke 
with demonstrated efficacy in numerous animal models of acute stroke. Long-term treatment with 
citicoline is safe and effective, improving post-stroke cognitive decline and enhancing patients’ 
functional recovery. Prolonged citicoline administration at optimal doses has been demonstrated to be 
remarkably well tolerated and to enhance endogenous mechanisms of neurogenesis and neurorepair, 
similar to those obtained with stem cells [92,93], contributing to physical therapy and rehabilitation. 
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